Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease

The goal of this clinical trial is to learn if ultrasound-guided stellate ganglion block (SGB), added to standard drug treatment, can improve thinking and memory in people with Alzheimer's disease. It will also learn about the safety of SGB. The main questions this study aims to answer are: Do people who receive SGB plus standard drug treatment have better global cognition, measured by the Mini-Mental State Examination (MMSE), 1 month after finishing the treatment course compared with people who receive standard drug treatment alone? How do anxiety, depression, quality of life, and ability to live independently change over 1 month, 3 months, and 6 months after treatment? What medical problems, if any, occur during or after SGB? Researchers will compare two groups: SGB plus standard drug treatment Standard drug treatment alone Participants will: Be randomly assigned to one of the two groups Receive the assigned treatment Complete study visits and assessments at baseline and at 1 month, 3 months, and 6 months after finishing the treatment course

NCT Number	NCT07351773
Lead Sponsor	Taizhou Second People's Hospital Collaborators: Taizhou Municipal Bureau of Science and Technology
Conditions	Alzheimer's Disease(AD), Cognitive Dysfunction
Enrollment	40 participants
Start Date	2025-01-26
Primary Completion	2025-06-29 (estimated)
Study Completion	2025-11-29 (estimated)
Updated on ClinicalTrials.gov	2026-01-21